Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 2;136(1):144-147.
doi: 10.1182/blood.2020006941.

Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study

Douglas Tremblay  1 , Maaike van Gerwen  2   3 , Mathilda Alsen  2 , Santiago Thibaud  1 , Alaina Kessler  1 , Sangeetha Venugopal  1 , Iman Makki  1 , Qian Qin  1 , Sirish Dharmapuri  1 , Tomi Jun  1 , Sheena Bhalla  1 , Shana Berwick  1 , Jonathan Feld  1 , John Mascarenhas  1 , Kevin Troy  1 , Caroline Cromwell  1 , Andrew Dunn  4 , William K Oh  1 , Leonard Naymagon  1
Affiliations

Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study

Douglas Tremblay et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.M. has received research funding from CTI Biopharma. A.D. has received research funding from Pfizer/Bristol-Myers Squibb, served on the scientific advisory board for Bristol-Myers Squibb, and received an honorarium from Johnson & Johnson. W.K.O. has acted as a consultant for Astellas, AstraZeneca, Bayer, Janssen, Sanofi, Sema4, and TeneoBio. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Survival and time-to-mechanical ventilation analysis in the propensity-matched AC cohort compared with no-AC/antiplatelet cohort. Propensity matching yielded 139 patients who received AC and 417 patients who did not receive AC or antiplatelet therapy; they were compared using Kaplan-Meier survival analysis. (A) There was no statistically significant difference in survival between those who received AC and the propensity-matched control group (P = .367). (B) There was no statistically significant difference in time-to-mechanical ventilation between the 2 groups (P = .742).
See this image and copyright information in PMC

References

    1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157-160. - PMC - PubMed
    1. Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239. - PubMed
    1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. - PMC - PubMed
    1. Thachil J, Tang N, Gando S, et al. . ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026. - PMC - PubMed
    1. Connors J, Levy J. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040. - PMC - PubMed

MeSH terms